Univest
Univest
  • Markets

Alembic Ltd Analyst Review 2027: Stake in Alembic Pharma Worth More Than Its Own Market Value

  • November 19, 2026
  • Posted by: Chaitanya Auti
  • Category: Market
No Comments
Alembic Ltd Analyst Review 2027: Stake in Alembic Pharma Worth More Than Its Own Market Value

Alembic Ltd Stock Snapshot (18 Nov 2026 close)

  • Current Market Price (CMP): ₹112.41
  • 52-Week High / Low: ₹118.23 / ₹70.46
  • Market Capitalisation: ₹2,889 crore
  • P/E Ratio vs Industry P/E: 8.1 vs 35.4
  • Latest Quarter (Q2 FY27) Revenue: ₹101.80 crore
  • Latest Quarter (Q2 FY27) Net Profit: ₹67.57 crore

Quick Answer: The Alembic Ltd analyst review 2027 finds no brokerage coverage as of November 2026. Q2 FY27 income was ₹101.80 crore and net profit ₹67.57 crore, down about 11% from ₹76.06 crore a year ago but far above ₹15.70 crore in the June quarter. The key point is its 28.54% stake in Alembic Pharmaceuticals, worth about ₹5,850 crore at current prices, roughly twice Alembic Ltd’s own market value of ₹2,889 crore. The Alembic Ltd share price target 2027 question is about how much of that holding discount narrows.

The Alembic Ltd analyst review 2027 covers Alembic Limited, the Vadodara-based group company whose main asset is its stake in listed drug maker Alembic Pharmaceuticals, alongside a land and real estate business. Readers looking for an Alembic Ltd share price target 2027 will not find a named brokerage target, so this review focuses on results and the value of its holdings.

Alembic Ltd closed at ₹112.41 on 18 November 2026, about 5% below its 52-week high of ₹118.23 and about 60% above its low of ₹70.46. This Alembic Ltd analyst review 2027 covers the September quarter and the Alembic Ltd stock outlook 2027.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • What Analysts Say in the Alembic Ltd Analyst Review 2027
  • Q2 FY27 Results in the Alembic Ltd Analyst Review 2027
  • How Alembic Ltd Makes Money
  • Growth Triggers in the Alembic Ltd Analyst Review 2027
  • Key Risks in the Alembic Ltd Analyst Review 2027
  • Alembic Ltd Analyst Review 2027: Stock at a Glance
  • Shareholding Trend
  • What to Watch After the Alembic Ltd Analyst Review 2027
  • Final Word on the Alembic Ltd Analyst Review 2027
  • Frequently Asked Questions
    • What does the Alembic Ltd analyst review 2027 show?
    • Is there an Alembic Ltd share price target 2027 from brokerages?
    • What does Alembic Ltd own?
    • Why does Alembic Ltd trade at a discount to its stake value?
    • Why is Alembic Ltd profit higher in the September quarter?
    • What risks does the Alembic Ltd analyst review 2027 highlight?
    • What should investors track after the Alembic Ltd analyst review 2027?

What Analysts Say in the Alembic Ltd Analyst Review 2027

Brokerage Rating Target Price Date
No verified coverage Not available Not available As of November 2026

No named brokerage publishes a target for Alembic Ltd. Holding companies are rarely covered because their value depends mainly on the listed companies they own.

The clearest reference point is the value of its stake in Alembic Pharmaceuticals. At that company’s market value of about ₹20,512 crore, a 28.54% stake is worth about ₹5,850 crore, against Alembic Ltd’s own market value of ₹2,889 crore. This Alembic Ltd analyst review 2027 explains that gap below.

Q2 FY27 Results in the Alembic Ltd Analyst Review 2027

Quarter Total Income EBITDA Net Profit
Sep 2026 (Q2 FY27) ₹101.80 crore ₹76.84 crore ₹67.57 crore
Jun 2026 (Q1 FY27) ₹54.70 crore ₹21.42 crore ₹15.70 crore
Mar 2026 (Q4 FY26) ₹62.18 crore ₹22.35 crore ₹9.61 crore
Sep 2025 (Q2 FY26) ₹120.78 crore ₹88.16 crore ₹76.06 crore

Income fell about 16% from a year ago and net profit fell about 11% to ₹67.57 crore. Against the June quarter, profit was more than four times higher.

The September quarter has been the strongest quarter in both years shown, which suggests seasonal income such as annual dividends lands in this period. For the Alembic Ltd analyst review 2027, full-year profit is a better guide than any single quarter.

How Alembic Ltd Makes Money

Alembic Ltd earns from its investments and from its own operating businesses.

  • Investment income: returns from its 28.54% stake in Alembic Pharmaceuticals and other holdings.
  • Real estate: land development and property projects in Vadodara.
  • Treasury income: income from surplus funds.
  • Group role: it is part of the promoter group of Alembic Pharmaceuticals.

FY26 income was about ₹313 crore with profit of about ₹126 crore, compared with ₹297 crore and ₹145 crore in FY25. Operating cash flow rose to about ₹120 crore in FY26 from ₹86 crore. Those figures frame this Alembic Ltd analyst review 2027.

Holding companies in India usually trade at a large discount to the value of their stakes, because investors cannot access the underlying company’s cash directly and the holding company’s own costs and taxes reduce the value that reaches its shareholders. Alembic Ltd’s discount of roughly 50% is wide even by those standards.

That gap can change when the underlying stock moves. Alembic Pharmaceuticals’ stock rose about 20% in one day after its Q2 FY27 results showed profit up 81%, which lifted the value of Alembic Ltd’s stake. Alembic Ltd has also moved towards its 52-week high, though the discount remains large.

For shareholders, the practical value comes through dividends. Alembic Ltd receives dividends from its pharma stake and passes part of its income on through its own payout, which is why its dividend yield of about 2.1% is higher than that of many companies of its size.

Growth Triggers in the Alembic Ltd Analyst Review 2027

  • Pharma stake value: a 28.54% holding worth about twice Alembic Ltd’s market value.
  • Strong pharma results: Alembic Pharmaceuticals profit rose 81% in Q2 FY27.
  • Real estate: land development in Vadodara adds operating income.
  • No debt: debt to equity is zero.
  • Dividend yield: about 2.1%, supporting the Alembic Ltd share price target 2027 case.

Key Risks in the Alembic Ltd Analyst Review 2027

  • Holding discount: the gap to stake value may never close.
  • Pharma dependence: value moves with Alembic Pharmaceuticals’ share price.
  • Lumpy profits: quarterly profit swings between about ₹10 crore and ₹76 crore.
  • Real estate cycles: land sales and project timing can vary.
  • No coverage: limited research and institutional interest, a point in the Alembic Ltd analyst review 2027.

Compare Alembic Ltd With Other Holding Company Stocks on the Univest Screener

Alembic Ltd Analyst Review 2027: Stock at a Glance

Metric Value
Share Price (18 Nov 2026 close) ₹112.41
52-Week High / Low ₹118.23 / ₹70.46
Market Capitalisation ₹2,889 crore
P/E (TTM) 8.1
Price to Book 1.08
Book Value per Share ₹104.20
Return on Equity 13.3%
Debt to Equity 0.00
Dividend Yield 2.13%
FY26 Income / Net Profit ₹313 crore / ₹126 crore

The P/E of about 8 and price to book value of about 1.08 look low, but book value carries the pharma stake at its accounting value rather than its market value. In this Alembic Ltd analyst review 2027, the stake’s market value is the more useful measure.

Shareholding Trend

Holder Sep 2025 Sep 2026 Change
Promoters 70.88% 71.41% Up 0.53 points
Foreign Investors (FII) 1.38% 1.34% Flat
Domestic Institutions (DII) 0.05% 0.05% Flat
Public 27.69% 27.20% Down 0.49 points

The promoter group holds about 71.4%, led by Nirayu Private Limited at 63.6% and Chirayu Amin at 3.2%. A small rise in promoter holding is a mild positive in the Alembic Ltd analyst review 2027.

Univest iOS App

Univest Android App

What to Watch After the Alembic Ltd Analyst Review 2027

  • Alembic Pharmaceuticals: its share price and results drive Alembic Ltd’s value.
  • Holding discount: whether the gap to stake value narrows.
  • Real estate: progress in Vadodara land projects.
  • Dividends: payouts from both companies.
  • Coverage: any research note would give an Alembic Ltd share price target 2027 reference.

Final Word on the Alembic Ltd Analyst Review 2027

The Alembic Ltd analyst review 2027 shows a debt-free holding company whose stake in Alembic Pharmaceuticals is worth about twice its own market value. Quarterly profit is lumpy, and the holding discount is the central question.

The Alembic Ltd stock outlook 2027 depends on Alembic Pharmaceuticals’ performance and on whether the discount narrows. Univest does not give a buy or sell call.

Disclaimer: This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.

Frequently Asked Questions

What does the Alembic Ltd analyst review 2027 show?

It shows a holding company trading well below the value of its main stake. Q2 FY27 profit was ₹67.57 crore, down about 11% from a year ago. Its 28.54% stake in Alembic Pharmaceuticals is worth about ₹5,850 crore.

Is there an Alembic Ltd share price target 2027 from brokerages?

No named brokerage target could be verified as of November 2026. The stock closed at ₹112.41 on 18 November 2026. The market value is ₹2,889 crore.

What does Alembic Ltd own?

It owns 28.54% of Alembic Pharmaceuticals and runs a land and real estate business in Vadodara. It is part of the promoter group of the pharma company. FY26 profit was about ₹126 crore.

Why does Alembic Ltd trade at a discount to its stake value?

Holding companies usually trade below the value of their stakes because shareholders cannot access the underlying cash directly. Alembic Ltd’s discount is roughly 50%. Costs and taxes at the holding level also reduce value.

Why is Alembic Ltd profit higher in the September quarter?

The September quarter was the strongest in both FY26 and FY27, at ₹76.06 crore and ₹67.57 crore. This suggests seasonal income such as annual dividends lands then. June quarter profit was only ₹15.70 crore.

What risks does the Alembic Ltd analyst review 2027 highlight?

The main risks are a persistent holding discount, dependence on Alembic Pharmaceuticals and lumpy profits. Quarterly profit has ranged from about ₹10 crore to ₹76 crore. Institutional interest is very low.

What should investors track after the Alembic Ltd analyst review 2027?

Track Alembic Pharmaceuticals’ share price and results. Watch whether the holding discount narrows and how the Vadodara real estate business develops. Dividend payouts also matter.



2027 Alembic Ltd Analyst Review Holding Company and Real Estate

Leave a Reply Cancel reply